Genotypic testing for human immunodeficiency virus type 1 drug resistance

Area of Science:

• Virology
• Molecular Biology
• Pharmacology

Background:

• 16 approved human immunodeficiency virus type 1 (HIV-1) drugs exist in three classes: protease inhibitors, nucleoside/nucleotide reverse transcriptase (RT) inhibitors, and nonnucleoside RT inhibitors.
• HIV-1 drug resistance arises from mutations in protease and RT enzymes, the targets of these medications.
• Resistance mutations develop in treated individuals due to selective drug pressure and can be transmitted to new infections.

Purpose of the Study:

• To review the genetic mechanisms of HIV-1 drug resistance.
• To summarize data linking specific RT and protease mutations to drug resistance.
• To support the use of genotypic testing for guiding HIV therapy selection.

Main Methods:

• Review of published literature on HIV-1 drug resistance mutations.
• Analysis of genotypic and phenotypic data linking mutations to drug susceptibility.
• Synthesis of expert panel recommendations on HIV-1 resistance testing.

Main Results:

• Specific mutations in HIV-1 protease and RT enzymes confer resistance to approved antiretroviral drugs.
• Genotypic testing for protease and RT mutations provides prognostic value for treatment outcomes.
• Understanding mutation-drug relationships aids in selecting effective HIV treatment regimens.

Conclusions:

• Genetic mechanisms of HIV-1 drug resistance are well-defined.
• Protease and RT mutations are key determinants of treatment response.
• Susceptibility testing, guided by genotypic data, is essential for personalized HIV therapy.